Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21997852 | 1.00 | PDK1 (0.37) | PDK1 | |
| SCHEMBL21997230 | 1.00 | PDK1 (0.37) | PDK1 | |
| SCHEMBL28555385 | 0.84 | SMN1; SMN2 (0.42) | PDK1 | |
| SCHEMBL22168147 | 0.80 | PDK1 (0.39) | PDK1 | |
| SCHEMBL28619043 | 0.80 | PDK1 (0.39) | PDK1 | |
| SCHEMBL26079269 | 0.76 | DPP4 (0.32) | PDK1 | |
| SCHEMBL15920687 | 0.76 | USP2 (0.51) | — | |
| SCHEMBL15920709 | 0.76 | USP2 (0.51) | — | |
| SCHEMBL15920689 | 0.76 | USP2 (0.51) | — | |
| SCHEMBL29176903 | 0.75 | PDK1 (0.33) | PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113272301-B | Heterocyclic compound, intermediate, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-112409331-B | Heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-02-01 | — | — | US | disclosed |
| US-20230406850-A1 | CRYSTALLINE FORM OF HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-12-21 | — | — | US | disclosed |
| US-20230406851-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-12-21 | — | — | US | disclosed |
| CN-116635389-A | Morpholine derivative, pharmaceutical composition and application thereof | 上海海雁医药科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| EP-4198034-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2023-06-21 | — | — | EP | disclosed |
| EP-4169921-A1 | CRYSTALLINE FORM OF HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| CN-115835867-A | Benzimidazole derivative, preparation method and medical application thereof | 上海拓界生物医药科技有限公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-2951177-B1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NEOMED INST (CA) | 2018-04-04 | — | — | EP | disclosed |
| US-20180015099-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| US-9814725-B2 | Imidazopyridine compounds and uses thereof | NEOMED INSTITUTE (CA) | 2017-11-14 | — | — | US | disclosed |
| US-20170143730-A1 | Imidazopyridine Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-9598409-B2 | Imidazopyridine compounds and uses thereof | NEOMED INSTITUTE (CA) | 2017-03-21 | — | — | US | disclosed |
| CN-105324380-A | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors | ABBVIE INC | 2016-02-10 | — | — | CN | disclosed |
| CN-105246890-A | Pyrrolo[2, 3-b]pyridine cdk9 kinase inhibitors | ABBVIE INC | 2016-01-13 | — | — | CN | disclosed |
| US-20150361078-A1 | Imidazopyridine Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| EP-2951177-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | Neomed Institute (CA) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014117274-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NEOMED INSTITUTE (CA) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406851-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | PDK1 852/4885 |
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | P2RX7, P2RX3, P2RX5 | PDK1 395/4885 |
| US-20230406850-A1 | CRYSTALLINE FORM OF HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX6 | PDK1 2758/4885 |
| US-20150361078-A1 | Imidazopyridine Compounds and Uses Thereof | NISCH, ABL1, PAICS | PDK1 852/4885 |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | PDK1 1951/4885 |
| US-20180015099-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | PDK1 852/4885 |
| US-20170143730-A1 | Imidazopyridine Compounds and Uses Thereof | NISCH, ABL1, PAICS | PDK1 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.